Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis.
Farid Javandoust GharehbaghSoheil RoshanzamiriMohammad FarjamiFirouze HatamiLegha LotfollahiNeda KazeminiaFatemeh HatamiShervin ShokouhiIlad Alavi DarazamPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Our findings indicate a lower incidence of mortality in the L-AMB group compared to the NLAMB group. No statistically significant difference was observed in the incidence of breakthrough infection between the two groups. L-AMB administration is associated with nephropathy and hypokalemia. However, the refusal to continue treatment due to adverse effects is not significantly high.